Adult acute lymphoblastic leukemia (ALL) regimens now include targeted therapies and immunotherapy, which lower chemotherapy exposure and change which patients need allogeneic stem cell transplantation (alloSCT).
Blinatumomab, inotuzumab ozogamicin, and potent BCR::ABL1 tyrosine kinase inhibitors have improved outcomes in defined patient groups. Measurable residual disease increasingly decides who needs treatment intensification or transplantation (Jabbour and Kantarjian, 2026). Randomized trials support several of these approaches. Frontline CAR T-cell consolidation and wider chemotherapy replacement remain investigational.
Background: Why Adult ALL Lags Behind Pediatric ALL
Cure rates in childhood ALL exceed 80-90%. Historical five-year overall survival in adults is about 50%. Adults are more likely to have adverse genomic features, comorbidities, and treatment-related complications, which limit tolerance of prolonged intensive chemotherapy, especially at age 60 years or older.
Conventional regimens run for years, and cumulative toxicity can prevent completion. Relapse remains the main concern in patients with high-risk molecular abnormalities or persistent MRD.
Blinatumomab, a bispecific antibody that engages CD3-positive T cells against CD19-positive leukemia cells, improved survival when added to frontline B-cell ALL treatment. Inotuzumab ozogamicin, a CD22-directed antibody-drug conjugate, has been integrated into lower-intensity regimens. CAR T cells produce deep remissions in relapsed or refractory disease,and earlier CAR T-cell use, at low disease burden, is under study as a way to reduce the need for transplantation.
Ph-Negative B-Cell ALL
In CALGB 10403, pediatric-inspired chemotherapy in 295 patients aged 17-39 years produced a 10-year OS of 56% and event-free survival of 44%. Ten-year OS was 85% in patients who were MRD-negative after induction versus 52% in those with persistent MRD. Ph-like ALL was associated with inferior survival.
The randomized E1910 trial enrolled adults aged 30–70 years with Ph-negative B-cell ALL who were MRD-negative after intensive induction and consolidation. Adding blinatumomab to consolidation improved 3-year OS from 68% to 85% over chemotherapy alone. The benefit extended to patients who were MRD-negative by conventional assessment, beyond the established indication of persistent measurable disease. It also held in younger adults and in high-risk subgroups, including Ph-like ALL.
Hyper-CVAD With Blinatumomab and Inotuzumab
MD Anderson replaced four consolidation courses in Hyper-CVAD with blinatumomab, reducing intensive courses from eight to four (about 50%) and maintenance from 30 courses to 15. Inotuzumab was later added to every other course at a cumulative dose of 2.4 mg/m², with further chemotherapy reduction.
Among 75 patients with a median age of 33 years, 37 received inotuzumab and 38 did not. All achieved complete remission. MRD negativity was reached in 95% by multiparameter flow cytometry and 76% by next-generation sequencing. Four-year EFS was 83% and OS 91%, and 24 patients (32%) proceeded to alloSCT. On multivariable analysis, inotuzumab was the only factor significantly associated with OS. Its association with EFS did not reach significance.
A propensity-score comparison of 55 patients treated with Hyper-CVAD plus blinatumomab, with or without inotuzumab, against 55 treated with conventional Hyper-CVAD showed five-year OS of 90% versus 63% and EFS of 86% versus 57%. Both analyses were nonrandomized. A randomized trial of Hyper-CVAD plus blinatumomab with or without inotuzumab is ongoing (NCT02877303).
Higher cumulative inotuzumab doses raise the risk of hepatic sinusoidal obstruction syndrome/veno-occlusive disease, particularly in patients who proceed to alloSCT, and the cap in this regimen likely mitigates it. Cooperative group trials that added antibody-based therapy to frontline treatment, including AALL1732 and Alliance A041501, have reported later toxicities and deaths in remission.
Older Adults With B-Cell ALL
Intensive chemotherapy historically produced complete remission rates of 60-90% in older patients, but three-year survival was generally below 15%. Treatment-related mortality, prolonged cytopenias, and infections limited its benefit.
Mini-Hyper-CVD omits doxorubicin and lowers the doses of other agents, with inotuzumab and blinatumomab added. Among 83 patients with a median age of 67 years, complete remission was 99% and MRD negativity 93%. Five-year progression-free survival was 46% and OS 50%.
Outcomes were poor at age 70 years or older: 20 of 28 patients died, 17 of them in remission. In patients aged 60 years or older, the cumulative risk of therapy-related myeloid neoplasms was 20-25%, particularly in TP53-mutated ALL.
Chemotherapy-Free Inotuzumab and Blinatumomab
For patients older than 70 years, or aged 60 years or older and unfit for chemotherapy, the review describes a chemotherapy-free regimen of inotuzumab and blinatumomab with minimal vincristine and corticosteroids in induction. In an MD Anderson cohort of 18 patients (median age 76 years, half with TP53-mutated ALL), complete remission or complete remission with incomplete hematologic recovery (CRi) was 94% and flow MRD negativity 89%. Two-year EFS was 51% and OS 50%.
The Alliance A041703 study tested inotuzumab followed by blinatumomab in older adults with encouraging outcomes. Patients with detectable MRD by PCR at any time point had significantly worse EFS and OS.
Ph-Positive ALL: Blinatumomab Plus Ponatinib Beats Chemotherapy Plus Imatinib
TKIs improved outcomes when combined with chemotherapy. Blinatumomab has since allowed regimens that avoid intensive chemotherapy in many patients. Early studies combining blinatumomab with dasatinib or ponatinib showed high molecular response rates. Ponatinib is of particular interest because it inhibits BCR::ABL1 including the T315I resistance mutation.
GIMEMA ALL2820
The randomized phase III GIMEMA ALL2820 trial compared blinatumomab plus ponatinib (158 patients) with chemotherapy plus imatinib (78 patients) in newly diagnosed disease. Complete remission was 94% versus 79%, and MRD negativity after two cycles was 70% versus 59%. 18-month OS was 94% versus 77%.
Patients with persistent MRD, refractory disease, or ABL1 kinase domain mutations could cross over to blinatumomab. Thirty-one did so, and their 18-month OS was 97%. The comparator used imatinib, so the trial establishes the benefit of the whole blinatumomab-ponatinib regimen but not the contribution of each component.
High Presenting Leukocyte Count Marks a Relapse-Prone Subgroup
In the phase II blinatumomab-ponatinib study, a presenting white blood cell count of at least 70 × 10⁹/L carried a three-year cumulative relapse incidence of 31%, versus 6.7% with lower counts. Central nervous system relapse accounted for a substantial share of events.
MD Anderson added high-dose methotrexate and cytarabine consolidation for these patients and is exploring CAR T consolidation. Chemotherapy-free treatment may suit many Ph-positive patients, but this subgroup may still need additional therapy.
IKZF1plus: Prognosis Differs by TKI
The IKZF1plus genotype was associated with worse disease-free survival with blinatumomab-dasatinib (46% versus 83% in patients without it). With blinatumomab-ponatinib, relapse incidence did not differ with or without IKZF1plus (16% versus 20%). Ponatinib may overcome the poor prognosis of IKZF1plus, but the authors note that more robust prospective analyses are needed.
MRD-Guided Transplant Decisions
NGS-based MRD testing reaches a sensitivity approaching 10⁻⁶, below that of many flow cytometry assays. In a study of blinatumomab for persistent MRD, NGS MRD negativity predicted favorable long-term outcomes. Among patients who stayed NGS MRD-positive after blinatumomab, a landmark analysis showed two-year relapse-free survival of 63% with alloSCT versus 10% without.
NGS MRD does not override disease genetics. Patients with KMT2A-rearranged ALL are referred for alloSCT in first remission regardless of NGS MRD status.
Approximately 20-25% of patients treated with blinatumomab-ponatinib become NGS MRD-negative while retaining low-level BCR::ABL1 transcripts. These transcripts may come from nonlymphoblastic cells, including myeloid cells, and don’t always indicate persistent ALL.
Frontline CAR T Consolidation: Early Data Only
CAR T cells are most active at low disease burden, which prompted trials of consolidation in first remission. The rationale is better disease control with fewer severe inflammatory toxicities in patients with minimal disease.
Early phase II studies in newly diagnosed high-risk ALL reported NGS MRD negativity approaching 100% and one-year OS of 90-100%. One reported no grade 2 or higher cytokine release syndrome (CRS) and no immune effector cell-associated neurotoxicity syndrome (ICANS). The studies are small, and follow-up is too short to show whether remissions hold without further therapy or transplantation.
The review describes CAR T consolidation for selected high-risk patients and for those with persistent NGS MRD after blinatumomab. Patients who remain NGS MRD-positive after CAR T therapy and show minimal CAR T expansion or persistence are recommended for alloSCT.
T-Cell ALL: Chemotherapy Remains the Backbone
T-cell ALL has few targeted options. Treatment relies on chemotherapy with nelarabine and asparaginase. A modified Hyper-CVAD regimen adding nelarabine, peg-asparaginase, and venetoclax produced a two-year PFS of 88% in 46 patients, versus 64% with the original regimen. Two-year OS was numerically higher, but the difference was not statistically significant. AlloSCT is still considered for early T-cell precursor ALL, given its adverse biology and relapse risk.
CD7-Directed CAR T Cells
CD7 is expressed on both malignant and normal T cells, so CD7-directed CAR T cells risk attacking one another (fratricide). Investigational products use gene editing or other engineering strategies to avoid this. Early-phase studies of allogeneic CD7 CAR T products reported response rates of at least 73% with high MRD negativity. Severe CRS, prolonged cytopenias, and late infections remain concerns. No CD7-directed product was commercially available for T-cell ALL at the time of the review.
Relapsed or Refractory ALL: Deeper Remission Before CAR T or Transplantation
Salvage chemotherapy historically produced complete remission in about 40% of patients and three-year OS below 10-12%. Blinatumomab and inotuzumab improved remission rates, but long-term survival stayed limited when either was used alone.
Dose-dense mini-Hyper-CVD with inotuzumab and blinatumomab produced an overall response rate of 100% among 25 patients, with complete remission in 79% and NGS MRD negativity in 95%. Estimated two-year EFS was 69% and OS 77%. The cohort was small and needs validation.
Obecabtagene Autoleucel
Obecabtagene autoleucel is a CD19-directed CAR T product for adult relapsed or refractory B-cell ALL. In the FELIX trial, 127 patients were treated, and the complete remission or CRi rate was 78%. At a median follow-up of 33 months, two-year EFS was 43% and OS 46%. Patients with deep NGS MRD negativity and CAR T persistence had particularly favorable outcomes.
Post-CAR T transplantation decisions are based on prior remission duration, molecular response, CAR T expansion and persistence. Identifying patients who can safely skip transplantation remains unresolved.
Next Steps
Ongoing trials are testing how far chemotherapy can be reduced in Ph-negative disease and which Ph-positive patients can avoid both chemotherapy and transplantation. New bispecific antibodies, subcutaneous immunotherapy formulations, and CD7-directed cellular therapies may broaden options. Unmet need persists in KMT2A-rearranged ALL, TP53-mutated disease, complex karyotypes, early T-cell precursor ALL, and older adults with limited treatment tolerance.
Source: Jabbour E, Kantarjian H. Adult acute lymphoblastic leukemia: incorporation of recent advances into current treatment strategies. Blood Cancer J. 2026;16:162. doi:10.1038/s41408-026-01566-z.